Paper3390835
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.
Kune GA and 2 others. Cancer Res, 1988. Cited by 641 papers, by iCite.
Cite this record
ConductScience Library. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Papers, record 3390835. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3390835
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colonic Neoplasms | Major topic |
| Epidemiologic Methods | Major topic |
| Rectal Neoplasms | Major topic |
| Aged | |
| Australia | |
| Chronic Disease | |
| Combined Modality Therapy | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Risk Factors |
Source PubMed
Cited by181
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 641 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42626236 | Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth. | Front Oncol | 2026 | https://conductscience.org/library/papers/42626236 | PubMed |
| 41508334 | Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis". | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41508334 | PubMed |
| 40619604 | Precision Prevention Studies: A Targeted Approach to Cancer Prevention. | Cancer Prev Res (Phila) | 2025 | https://conductscience.org/library/papers/40619604 | PubMed |
| 40573208 | Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40573208 | PubMed |
| 40285986 | NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/40285986 | PubMed |
| 39766102 | The Potential Therapeutic Value of Aspirin in Anaplastic Thyroid Cancer. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39766102 | PubMed |
| 39600254 | Type II diabetes and metformin use does not affect colorectal cancer prognosis. | Int J Cancer | 2025 | https://conductscience.org/library/papers/39600254 | PubMed |
| 39546469 | Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. | JCO Precis Oncol | 2024 | https://conductscience.org/library/papers/39546469 | PubMed |
| 39445288 | Exploring Aspirin's Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence. | Cureus | 2024 | https://conductscience.org/library/papers/39445288 | PubMed |
| 39064188 | Aspirin in Primary Prevention: Looking for Those Who Enjoy It. | J Clin Med | 2024 | https://conductscience.org/library/papers/39064188 | PubMed |
| 38791445 | Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38791445 | PubMed |
| 38675399 | The 125th Anniversary of Aspirin-The Story Continues. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38675399 | PubMed |
| 38106409 | Decoding the role of platelets in tumour metastasis: enigmatic accomplices and intricate targets for anticancer treatments. | Front Immunol | 2023 | https://conductscience.org/library/papers/38106409 | PubMed |
| 38064111 | Using aspirin to prevent and treat cancer. | Inflammopharmacology | 2024 | https://conductscience.org/library/papers/38064111 | PubMed |
| 37663811 | Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action. | Toxicol Res (Camb) | 2023 | https://conductscience.org/library/papers/37663811 | PubMed |
| 37513924 | The Effect of Acetylsalicylic Acid, as a Representative Non-Steroidal Anti-Inflammatory Drug, on the Activity of Myeloperoxidase. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513924 | PubMed |
| 37221467 | An integrative review of nonobvious puzzles of cellular and molecular cardiooncology. | Cell Mol Biol Lett | 2023 | https://conductscience.org/library/papers/37221467 | PubMed |
| 37108226 | Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37108226 | PubMed |
| 36647071 | Aspirin increases chemosensitivity of colorectal cancer cells and inhibits the expression of toll-like receptor 4. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/36647071 | PubMed |
| 36189951 | Fifty years with aspirin and platelets. | Br J Pharmacol | 2023 | https://conductscience.org/library/papers/36189951 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3390835
GET https://conductscience.org/api/papers/v1/3390835/cited_by?page=2